Class 2 Medicines Recall (action within 48 hours): COSOPT Preservative-Free, 20mg/ml +5mg/ml, eye drops, solution, single-dose container – Merck Sharp & Dohme Limited (EL (14)A/02)
Merck Sharp & Dohme Limited COSOPT Preservative-Free, 20mg/ml +5mg/ml, eye drops, solution, single-dose container (Dorzolamide / Timolol) PL 00025/0698 Batch number Expiry Date Pack size First distributed MK13D002 30 April 2015 60 single dose containers 9 September 2013 MK13D004 30 April 2015 60 single dose containers 4 July 2013 Merck Sharp and Dohme is recalling
Survey results show under resourced eye clinics put patients’ sight at risk
Press Release UK survey by the Macular Society and the Royal College of Ophthalmologists highlights concerns over eye clinic capacity Thousands of elderly people with eye disease are receiving poor or very poor NHS services according to a survey of hospital ophthalmologists. The survey, by the Macular Society and the Royal College of Ophthalmologists, asked
UK National Screening Committee policy on Vision defects screening in children
College Statement The Royal College of Ophthalmologists supports the recommendation of the National Screening Committee that screening for visual impairment in children, between the ages of 4 and 5 years, should be offered by an orthoptic-led service.http://www.screening.nhs.uk/vision-child The College strongly advocates early screening for the detection of visual problems and eye disorders in children at
MHRA Drug Safety Alert: Dorzolomide hydrochloride/timolol maleate (Cosopt) preservative-free single-dose eye drops: reports of eye injury
Dorzolomide hydrochloride/timolol maleate (Cosopt) preservative-free single-dose eye drops are used to treat glaucoma. The MHRA is aware of 69 complaints in the UK with this product after the introduction of a new design of dropper in July 2013. These reports include scratches to the cornea, and difficulty in administration of the drops onto the eye.
Response to NICE announcing their positive draft guidance for Eylea® for the treatment of macular oedema secondary to CRVO
College Statement The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). We hope that this decision will help the clinical commissioning groups to support the rapid implementation of the final